<DOC>
	<DOCNO>NCT00002951</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy plus radiation therapy treat patient head neck cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine locoregional control rate , time failure , need salvage surgery overall survival patient intermediate stage cancer oral cavity , pharynx , larynx , paranasal sinus , cervical esophagus . - Measure impact concomitant Hyper-FHX radiotherapy organ preservation , organ function quality life parameter . - Identify possible prognostic factor toxic effect response perform pharmacologic monitoring . OUTLINE : Patients receive concomitant chemoradiotherapy curative intent . Patients microscopic macroscopic residual disease 6 week completion chemoradiotherapy receive surgical salvage procedure . The first cycle chemotherapy begin PO dos hydroxyurea every 12 hour day 0-5 . Fluorouracil give IV day 0-4 . Radiation therapy BID give day 1-6 . Cycles repeat every 14 day total 5 cycle . The disease reevaluate 4-6 week completion treatment , every 3 month 1 year , yearly . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis carcinoma Stage IIIII ( T2 , T3 , N0 T13 , N1 ) carcinoma head neck , include : oral cavity , pharynx , larynx , paranasal sinus , cervical esophagus No N2 N3 Measurable disease require PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 03 Life expectancy : Anticipated survival 34 year ( median ) Hematopoietic : WBC count least 3.5/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Not specify Cardiovascular : Not specify Pulmonary : Not specify Other : No infection severe medical illness Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : No prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage II lip oral cavity cancer</keyword>
	<keyword>stage III lip oral cavity cancer</keyword>
	<keyword>stage II hypopharyngeal cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage II laryngeal cancer</keyword>
	<keyword>stage III laryngeal cancer</keyword>
	<keyword>stage II paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage III paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage II oropharyngeal cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
</DOC>